Protective effects of angiotensin II Type 1 receptor blocker on cerebral circulation independent of blood pressure

Experimental Neurology

Volumn 210, Issue 2, 2008, Pages 441-448

  Kumai, Yasuhiro ^a   Ooboshi, Hiroaki ^a   Ago, Tetsuro ^a   Ishikawa, Eiichi ^a   Takada, Junichi ^a   Kamouchi, Masahiro ^a   Kitazono, Takanari ^a   Ibayashi, Setsuro ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor; Autoregulation; Cerebral blood flow; Free radicals; Remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; HYDROETHIDINE; SUPEROXIDE; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; BASILAR ARTERY; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN CIRCULATION; CHEMOLUMINESCENCE; CHRONIC DRUG ADMINISTRATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEMORRHAGIC HYPOTENSION; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THORACIC AORTA; TREATMENT DURATION; WISTAR KYOTO RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; BASILAR ARTERY; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CAROTID ARTERY, COMMON; CEREBROVASCULAR CIRCULATION; MALE; MIDDLE CEREBRAL ARTERY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SUPEROXIDES; TIME FACTORS;

EID: 41149123416     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.11.028     Document Type: Article

References (42)

1. Ago T., Nunoi H., Ito T., and Sumimoto H. Mechanism for phosphorylation-induced activation of the phagocyte NADPH oxidase protein p47phox. Triple replacement of serines 303, 304, and 328 with aspartates disrupts the SH3 domain-mediated intramolecular interaction in p47phox, thereby activating the oxidase. J. Biol. Chem. 274 (1999) 33644-33653
2. Ago T., Kitazono T., Ooboshi H., Iyama T., Han Y.H., Takada J., Wakisaka M., Ibayashi S., Utsumi H., and Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 109 (2004) 227-233
3. Baumbach G.L., Dobrin P.B., Hart M.N., and Heistad D.D. Mechanics of cerebral arterioles in hypertensive rats. Circ. Res. 62 (1988) 56-64
4. Baumbach G.L., and Heistad D.D. Remodeling of cerebral arterioles in chronic hypertension. Hypertension. 13 (1989) 968-972
5. Baumbach G.L., Sigmund C.D., and Faraci F.M. Cerebral arteriolar structure in mice overexpressing human renin and angiotensinogen. Hypertension. 41 (2003) 50-55
6. Baumbach G.L., Didion S.P., and Faraci F.M. Hypertrophy of cerebral arterioles in mice deficient in expression of the gene for CuZn superoxide dismutase. Stroke. 37 (2006) 1850-1855
7. Brosnan M.J., Hamilton C.A., Graham D., Lygate C.A., Jardine E., and Dominiczak A.F. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J. Hypertens. 20 (2002) 281-286
8. Cai H., Ibayashi S., Yao H., Sugimori H., Sadoshima S., and Fujishima M. The alpha 1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagic hypotension in anesthetized hypertensive rats. Eur. J. Pharmacol. 286 (1995) 249-253
9. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., and LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
10. Dayal S., Brown K.L., Weydert C.J., Oberley L.W., Arning E., Bottiglieri T., Faraci F.M., and Lentz S.R. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc. Biol. 22 (2002) 1996-2002
11. Dobrian A.D., Schriver S.D., and Prewitt R.L. Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension. Hypertension. 38 (2001) 361-366
12. Duke L.M., Paull J.R., and Widdop R.E. Cardiovascular status following combined angiotensin-converting enzyme and AT1 receptor inhibition in conscious spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 30 (2003) 317-322
13. Dupuis F., Atkinson J., Liminana P., and Chillon J.M. Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J. Hypertens. 23 (2005) 1061-1066
14. Fischli W., Hefti F., and Clozel J.P. Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats. Br. J. Clin. Pharmacol. 27 (1989) 151S-158S
15. Fujishima M., and Omae T. Lower limit of cerebral autoregulation in normotensive and spontaneously hypertensive rats. Experientia. 32 (1976) 1019-1021
16. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74 (1994) 1141-1148
17. Griendling K.K., Ushio-Fukai M., Lassegue B., and Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension. 29 (1997) 366-373
18. Griendling K.K., Sorescu D., Lassègue B., and Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2175-2183
19. Harper S.L. Antihypertensive drug therapy prevents cerebral microvascular abnormalities in hypertensive rats. Circ. Res. 60 (1987) 229-237
20. Hornig B., Landmesser U., Kohler C., Ahlersmann D., Spiekermann S., Christoph A., Tatge H., and Drexler H. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 103 (2001) 799-805
21. Ibayashi S., Ogata J., Sadoshima S., Fujii K., Yao H., and Fujishima M. The effect of long-term antihypertensive treatment on medial hypertrophy of cerebral arteries in spontaneously hypertensive rats. Stroke 17 (1986) 515-519
22. Ito T., Yamakawa H., Bregonzio C., Terron J.A., Falcon-Neri A., and Saavedra J.M. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke. 33 (2002) 2297-2303
23. Li J.S., Sharifi A.M., and Schiffrin E.L. Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR. J. Cardiovasc. Pharmacol. 30 (1997) 75-78
24. Li P.F., Dietz R., and von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation. 96 (1997) 3602-3609
25. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A., and SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE), 2003: principal results of a randomized double-blind intervention trial. J. Hypertens. 21 (2003) 875-886
26. Mohazzab K.M., Kaminski P.M., and Wolin M.S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am. J. Physiol. 266 (1994) H2568-H2572
27. 2 receptor stimulation increases cerebrovascular resistance during hemorrhagic hypotension in rats. Regul Pept. 52 (1994) 21-29
28. Nishimura Y., Ito T., and Saavedra J.M. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 31 (2000) 2478-2486
29. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., and Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation Contribution to alterations of vasomotor tone. J. Clin. Invest. 97 (1996) 1916-1923
30. Rao G.N., and Berk B.C. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 70 (1992) 593-599
31. Sadoshima S., Fujii K., Yao H., Kusuda K., Ibayashi S., and Fujishima M. Regional cerebral blood flow autoregulation in normotensive and spontaneously hypertensive rats-effects of sympathetic denervation. Stroke. 17 (1986) 981-984
32. Schrader J., Luders S., Kulschewski A., Berger J., Zidek W., Treib J., Einhäupl K., Diener H.C., Dominiak P., and Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group: The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 34 (2003) 1699-1703
33. Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., Zidek W., Dominiak P., Diener H.C., and MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
34. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
35. 2 receptor ligands modulate the upper limit of cerebral blood flow autoregulation in rats. J. Cereb. Blood Flow. Metab. 13 (1993) 298-303
36. Suzuki H., Swei A., Zweifach B.W., and Schmid-Schönbein G.W. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats. Hydroethidine microfluorography. Hypertension. 25 (1995) 1083-1089
37. Takada J., Ibayashi S., Nagao T., Ooboshi H., Kitazono T., and Fujishima M. Bradykinin mediates the acute effect of an angiotensin-converting enzyme inhibitor on cerebral autoregulation in rats. Stroke. 32 (2001) 1216-1219
38. Takada J., Ibayashi S., Ooboshi H., Ago T., Ishikawa E., Kamouchi M., Kitazono T., and Iida M. Valsartan improves the lower limit of cerebral autoregulation in rats. Hypertens Res. 29 (2006) 621-626
39. Touyz R.M. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension 44 (2004) 248-252
40. Vraamark T., Waldemar G., Strandgaard S., and Paulson O.B. Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation. J. Hypertens. 13 (1995) 755-761
41. Wienen W., Hauel N., Van Meel J.C., Narr B., Ries U., and Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110 (1993) 245-252
42. Zalba G., Beaumont F.J., San José G., Fortuño A., Fortuño M.A., Etayo J.C., and Díez J. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension. 35 (2000) 1055-1061